Drug Target Review

NOVEMBER 6, 2023

To bring us closer to curing cancer, a combination of effective drugs with non-overlapping mechanisms of action is required. 6 In all these examples, an effective backbone drug was first developed, before adding one or more drugs to establish the new regimens.

Small Molecule 111

Small Molecule Therapies Treatment Disease 111

Alta Sciences

APRIL 17, 2024

Five Promising Treatment Areas in Early-Phase Drug Development in 2024 aasimakopoulos Wed, 04/17/2024 - 15:52 Early-phase drug development is an ever-changing landscape, as emerging science leads to new promising areas of research for the treatment of human health issues.

Drug Development 52

Drug Development Treatment FDA Approval Drugs 52

Drug Target Review

JUNE 19, 2024

The other powerful benefit is that our cell lines can become any of the cell types of the human body – these cells have within their DNA the capability to become any of the more than 200 human cell types which you might want to manufacture. Just like small molecules and antibodies, cell therapies are changing how we treat patients.

Therapies 84

Therapies Small Molecule Pharmaceutical Companies Molecular Biology 84

Metabolite Tales Blog

OCTOBER 5, 2023

Missing metabolites Accounting for metabolites is a key activity in drug development programs. Trapping agents are described for reactive metabolites that could ordinarily be overlooked due to quenching with endogenous small molecules and protein nucleophiles.

Small Molecule 52

Small Molecule DNA Drug Development Drugs 52

The Premier Consulting Blog

JULY 9, 2023

During the development of new small molecule drug products, developers must conduct impurity and degradant evaluation at several points in the program and to varying degrees. What sets this guidance apart from ICH Q3A and ICH Q3B is that it applies to all stages of clinical development, not just to approval.

Small Molecule 52

Small Molecule DNA Drugs Clinical Development 52

The Pharma Data

JUNE 28, 2021

Broadens company’s oncology platform of Targeted Alpha Therapies / Acquisition includes actinium-225 labeled differentiated PSMA small molecule for the treatment of prostate cancer. It has been demonstrated to inflict difficult to repair damage to tumor cells by inducing DNA double strand breaks.

Small Molecule 52

Small Molecule Licensing Licensing Therapies 52

The Pharma Data

DECEMBER 14, 2020

. The current standard of care for GBM consists of de-bulking surgery followed by combined treatments with fractionated ionizing radiation (IR) and the DNA alkylating agent temozolomide (TMZ). Our mission is to transform and accelerate the cancer drug development process.

Clinical Trials 52

Clinical Trials DNA Drugs Therapies 52

Elrig

APRIL 29, 2024

Srinivasan has led the development of multiple computational pipelines to process data from different next generation sequencing techniques with applications in oncology, genome editing systems including CRISPR-Cas mediated DNA editing, and ADAR-mediated RNA editing.

Bioinformatics 59

Bioinformatics Drugs Molecular Biology Cell Based Assays 59

Vial

FEBRUARY 19, 2024

We can link small molecule drugs to a payload that would enter in the cell and kill it. We have the capability of different types of targets, whether small molecules or antibodies. Also, payloads that are permeable payloads and specifically microtubule inhibitors or DNA alkylators or chemo.

Small Molecule 52

Small Molecule Therapies Treatment Science 52

PLOS: DNA Science

SEPTEMBER 5, 2024

The most groundbreaking cancer drug approval was for Gleevec , with a mere 3-month trajectory at FDA before its approval in 2001. Gleevec is a small molecule that interferes with entry of an enzyme – a tyrosine kinase – that enables growth signals to enter specific cells and trigger division.

Treatment 70

Treatment FDA Approval DNA Small Molecule 70

The Premier Consulting Blog

APRIL 25, 2023

Opinions regarding how the new act will impact the industry vary, with predictions ranging from everything remaining at the status quo to the end of animal testing for new drug development and approvals. In the US, new small molecule drugs are developed under the requirements of Sections 505(b)(1) and 505(b)(2) of the FFDCA.

FDA 52

FDA Animal Testing Pharmacokinetics Pharmaceuticals 52

DrugBank

FEBRUARY 26, 2025

These strategies represent a shift in how antibiotics are discovered, developed, and deployed. Targeting Novel Bacterial Pathways Traditional antibiotics often target essential bacterial processes such as cell wall synthesis or DNA replication. AMPs disrupt bacterial membranes, making them less susceptible to resistance development.

Therapies 52

Therapies Pharmaceutical Companies Pharmacokinetics Treatment 52

Drug Target Review

JULY 18, 2024

Why is detecting cancers via liquid biopsy before they become visible on imaging important for drug development, not just diagnostics? We believe liquid biopsy is very helpful for oncology drug development because the reduction and clearance of circulating DNA occurs quickly before radiographic imaging is available.

Drug Development 59

Drug Development Clinical Trials Drugs Vaccine 59

Agency IQ

APRIL 19, 2024

MRD in multiple myeloma, specifically: The 2020 guidance states that “significant improvements in clinical outcomes of MM have spurred interest in the use of MRD as a potential surrogate endpoint to expedite drug development.” The analysis included 20 trials for 12,926 patients with IPD.

FDA 40

FDA Disease Trials Clinical Trials 40

Drug Target Review

DECEMBER 13, 2024

Innovations in payload substances, such as topoisomerase inhibitors (topo-1i), and next-generation DNA- damaging agents to replace older, more toxic agents. 7 Recent clinical studies highlight promising developments in c-MET-targeting ADCs for NSCLC. Antibody-drug conjugates: Principles and opportunities. 2024;347:122676.

Therapies 98

Therapies Treatment Clinical Trials Drugs 98

The Pharma Data

OCTOBER 26, 2020

Companies enter into exclusive license and co-development agreement to accelerate global reach of Tukysa (tucatinib), a small molecule tyrosine kinase inhibitor for the treatment of HER-2 positive cancers. (formerly known as Seattle Genetics, Inc.) Canada and Europe. Organon & Co.

Vaccine 40

Vaccine Trials Treatment Therapies 40

LifeSciVC

FEBRUARY 5, 2025

Transcription factors are well-known entities they are the hairclip-shaped molecules that when activated, travel into to the nucleus, grab onto DNA, and drive the transcription of genes into proteins.

Small Molecule 67

Small Molecule Targeted Protein Degradation Regulations Disease 67

Drug Target Review

DECEMBER 11, 2024

While LLMs are most commonly associated with consumer tools like ChatGPT, they can be trained on any text-based dataset, including DNA and protein sequences. Generative AI algorithms, known as large language models (LLMs), are useful for predicting and manipulating interactions between antibodies, TCRs and their targets.

Immune Response 52

Immune Response Engineering Therapies Small Molecule 52